Presbyopia used to be a condition we managed. We recommended readers, transitioned patients to progressive lenses, and told them meaningful intervention would come when the lens eventually needed to come out. That model worked—but it left patients waiting and practices on the sidelines of a growing refractive conversation.
That has changed significantly in recent years. Presbyopia is no longer a condition we simply accommodate; it has become a platform—the first refractive conversation many patients have with us, and a foundation for a longitudinal relationship that can span decades.
What's driving that shift isn't a single technology, but rather the convergence of several: new pharmacologic approvals, a maturing intraocular lens (IOL) landscape, advances in diagnostics, and, on the horizon, the real possibility of restoring true accommodation. Together, they are redefining both patient expectations and what a modern presbyopia practice looks like.
A Pharmacologic Category That Has Come of Age
The approval of pilocarpine 1.25% ophthalmic solution opened the door to pharmacologic presbyopia correction. Since then, the category has matured in meaningful ways.
We now have agents with distinct clinical profiles. Pilocarpine-based drops work primarily through pupil constriction to increase depth of focus. They are effective for situational use, particularly for patients who want near vision on demand without committing to a procedural intervention. That flexibility is a genuine advantage for the right patient.
Importantly, the pharmacologic category has continued to expand. Pilocarpine hydrochloride ophthalmic solution 0.4%,(Qlosi; Orasis Pharmaceuticals) offers a lower-dose, preservative-free pilocarpine option. Aceclidine ophthalmic solution 1.44% (Vizz; Lenz Therapeutics) introduces a different mechanism, focusing on contraction of the iris sphincter using aceclidine. The most recent evolution is combination pharmacologic therapy. Carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1% (Yuvezzi; Tenpoint Therapeutics, Ltd.) represents a fixed-dose combination approach designed to improve near vision through complementary mechanisms. Carbachol produces miosis, while brimonidine helps modulate pupil response and may reduce some of the tolerability issues associated with miotic therapy.
In practical terms, this evolution gives physicians more flexibility to match treatment selection to the patient’s visual goals, lifestyle, ocular surface condition, and tolerance for side effects. It allows us to individualize the discussion. Some patients may want situational near-vision support. Others may prefer a longer-duration or more routine daily option. Still others may use drops as a bridge while they consider corneal or lens-based approaches. The expanding drop category does not replace surgical planning; it widens the front end of the refractive funnel.
I want to emphasize, however, the strategic dimension of these drops—not just the clinical one. A patient who starts on a topical presbyopia agent is a patient who has entered a refractive relationship with your practice. They come back for follow-up. They ask questions. They become more engaged with their vision in a way that opens the door to conversations about corneal and lens-based options as their needs evolve. The drop is not the destination—it is the entry point.
The IOL Landscape: Predictability Is the New Differentiator
On the surgical side, the story of the past several years has been one of refinement rather than revolution—and that refinement matters clinically.
Extended-depth-of-focus (EDOF) lenses and enhanced monofocals have improved our ability to deliver a functional range of vision with fewer of the dysphotopsias that made earlier multifocal technology a harder conversation. For many patients, the visual experience with current-generation EDOF platforms feels more natural—less like a technology working around a limitation, and more like vision that simply functions well across distances.
That predictability has a practical consequence: It makes the conversation easier. When I can tell a patient with confidence that the technology has improved and that the halo complaints we used to manage are now far less common, they are more receptive. Realistic expectations, met consistently, build the trust that grows a referral-based refractive practice.
The next horizon in lens-based correction is true accommodation: IOLs that dynamically respond to the ciliary muscle to restore near vision the way the natural crystalline lens once did. Several platforms are in clinical trials. None are yet approved. But the science is advancing, and the possibility of a truly accommodating IOL within the next decade is real. When it arrives, it will change the surgical conversation for presbyopia entirely.
Corneal Options: Selective, Not Obsolete
Corneal refractive approaches to presbyopia have not disappeared, but they have become more precisely indicated. Blended vision LASIK remains a valuable option for patients who are not yet candidates for lens-based surgery but want more functional range than pharmacologic therapy alone can provide. The key is appropriate selection: patients who have previously adapted to monovision contact lenses, those with minimal higher-order aberrations, and those with realistic expectations for what corneal presbyopia correction achieves.
I think of corneal options as an important middle step in the refractive continuum—not a permanent solution for most, but a bridge that keeps patients engaged and satisfied while they move toward lens-based correction at the appropriate time.
The Real Advance: Smarter Patient Selection
If I were asked to name the single greatest improvement in presbyopia care over the past few years, I would not point to any specific technology. I would point to how we have become better at selecting patients for each option.
Ocular surface optimization has moved from an afterthought to a prerequisite. No presbyopia technology—pharmacologic, corneal, or lens-based—performs reliably on a compromised ocular surface. Identifying and treating dry eye disease, meibomian gland dysfunction, and surface irregularity before any intervention is now standard in a well-run presbyopia practice. It is also, I would argue, a differentiator: practices that do this consistently see better outcomes and fewer unhappy patients.
Diagnostic precision is also improving. Anterior segment imaging, wavefront analysis, and pupillometry allow us to characterize the individual patient’s optical system in ways that were not practical a decade ago. Artificial intelligence is beginning to assist in pattern recognition across these data sets, helping to predict who will respond well to which option and flagging patients who may be at risk for dissatisfaction. This is early, but promising.
Presbyopia as Practice Strategy: Why This Is the Right Moment
There is a case to be made (and I have made it to colleagues who pushed back) that presbyopia is replacing LASIK as the most reliable entry point into refractive care for the average practice. Not because presbyopia technology is more advanced than laser vision correction, but because the patient population is categorically larger, the entry barrier is lower, and the timeline of care is longer.
LASIK serves a specific window: motivated patients, typically in their 20s and 30s, with stable myopia or astigmatism. Presbyopia touches virtually everyone over 40. Those patients are already in your practice, presenting for routine care, contact lens evaluations, or mild dry-eye complaints. The question is whether you are having a refractive conversation with them or simply handing them a reading glasses prescription and moving on.
I recently had an experience that reinforced this point outside the traditional exam-lane setting. At a meeting I organized for more than 50 ophthalmologists, the presentation that generated the most conversation was presbyopia drops. Many middle-aged professionals immediately understood the problem because they were living it every day: taking orders from restaurant patrons, applying makeup, forgetting their readers, or feeling frustrated by the constant on-and-off cycle of glasses.
That response was insightful. These were not patients asking for “presbyopia management.” They were people who excitedly asked, “Is there really a drop that can help me see up close? Where can I get this?” The demand already exists. Many patients simply do not know that the conversation belongs in their ophthalmologist’s office.
Framing Presbyopia to Patients Changes the Economics
When you frame presbyopia as the beginning of a multi-decade refractive relationship, the economics change. Drops represent an accessible cash-pay entry point with high return visit rates. Corneal and lens-based procedures add premium revenue at appropriate transition points. Patient lifetime value, when this continuum is managed intentionally, is substantial. More importantly, the relationship becomes longitudinal rather than transactional: the patient who first asks about near-vision drops today may become the patient who later considers blended vision, premium cataract surgery, or lens-based refractive correction.
In a well-run presbyopia practice, growth follows good care. When patients feel heard, are appropriately selected, and are carefully counseled, practice growth becomes a byproduct of better clinical decision-making and a better patient experience. From an operational standpoint, integrating presbyopia care does not require a complete redesign of your practice, but it does require intentional workflow design. The most successful practices do not rely on the physician to introduce the conversation for the first time in the exam room. They build presbyopia into the patient journey from the beginning: website prompts or chatbots; intake forms that identify near-vision frustration; technicians trained to ask about reading glasses and digital device use; diagnostic protocols that include ocular surface assessment and pupillometry when appropriate; and patient education materials that frame presbyopia as a spectrum of options rather than a binary choice between readers and surgery.
This is where the practice-management opportunity becomes significant. Presbyopia lends itself to a structured continuum-of-care model: first identifying the patient’s functional needs, then optimizing the ocular surface, then matching the patient to the right entry point—whether that is a pharmacologic option, blended vision, premium lens technology, or continued monitoring until the timing is right.
The practices that succeed will be the ones that operationalize this category: creating clear decision trees, setting expectations consistently, tracking outcomes, and making sure every team member understands how to discuss presbyopia without overpromising. In that sense, presbyopia is not just a clinical opportunity, but also a patient-experience opportunity—and, when managed well, a durable refractive growth strategy.
Where We Are Headed
The next 5 years in presbyopia will bring longer-acting pharmacologic agents, true accommodating IOL options, and AI-assisted selection tools that reduce the variability in outcomes that still frustrate both patients and surgeons. But the goal remains unchanged: better functional vision, safer patient selection, clearer expectations, and elevated care that helps patients participate more fully in their daily lives.
Presbyopia is no longer a condition we work around; it is a platform we build on. Practices that recognize that shift and structure their approach accordingly will find that it becomes one of the most durable foundations of their refractive strategy.
